Dopamine up-regulates Th17 phenotype from individuals with generalized anxiety disorder

Journal of Neuroimmunology

Volumn 238, Issue 1-2, 2011, Pages 58-66

  Ferreira, Thais B ^a   Kasahara, Taissa M ^a   Barros, Priscila O ^a   Vieira, Morgana M M ^a   Bittencourt, Vera Carolina B ^a   Hygino, Joana ^a   Andrade, Regis M ^a   Linhares, Ulisses C ^a   Andrade, Arnaldo F ^b   Bento, Cleonice A ^a  

^a FEDERAL UNIVERSITY OF THE STATE OF RIO DE JANEIRO   (Brazil)

^b STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Dopamine; Generalized anxiety disorder; Glucocorticoid; IL 10 TGF ; Th17 Th1

Indexed keywords

DOPAMINE; GAMMA INTERFERON; GLUCOCORTICOID; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 21; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADULT; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL VIABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; FEMALE; GENERALIZED ANXIETY DISORDER; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOMODULATION; LYMPHOCYTE PROLIFERATION; MALE; PHENOTYPE; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TH17 CELL; UPREGULATION;

ADOLESCENT; ADULT; ANTIGENS, CD; ANXIETY DISORDERS; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; CYTOKINES; DOPAMINE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GLUCOCORTICOIDS; HUMANS; MALE; MITOGENS; PHENOTYPE; PHYTOHEMAGGLUTININS; TH17 CELLS; THYMIDINE; TRITIUM; TUBERCULIN; UP-REGULATION; YOUNG ADULT;

EID: 80052864950     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2011.06.009     Document Type: Article

References (77)

1. Affleck G., Urrows S., Tennen H., Higgins P., Pav D., Aloisi R. A dual pathway model of daily stressor effects on rheumatoid arthritis. Ann. Behav. Med. 1997, 19:161-170.
2. Agarwal S.K., Marshall G.D. Glucocorticoid-induced type 1/type 2 cytokine alterations in humans: a model for stress-related immune dysfunction. J. Interferon Cytokine Res. 1998, 18:1059-1068.
3. Andrade L., Walters E.E., Gentil V., Laurenti R. Prevalence of ICD-10 mental disorders in a catchment area in the city of São Paulo. Brazil. Soc. Psychiatry Psychiatr. Epidemiol. 2002, 37:316-325.
4. Arborelius L., Owens M.J., Plotsky P.M., Nemeroff C.B. The role of corticotropin-releasing factor in depression and anxiety disorders. J. Endocrinol. 1999, 160:1-12.
5. Arranz L., Guayerbas N., De la Fuente M. Impairment of several immune functions in anxious women. J. Psychosom. Res. 2007, 62(1):1-8.
6. Ashwell J.D., Lu F.W., Vacchio M.S. Glucocorticoids in T cell development and function. Annu. Rev. Immunol. 2000, 18:309.
7. Aviles H., Johnson M.T., Monroy F.P. Effects of cold stress on spleen cell proliferation and cytokine production during chronic Toxoplasma gondii infection. Neuroimmunomodulation 2004, 11(2):93-102.
8. Bencsics A., Sershen H., Baranyi M., Hashim A., Lajtha A., Vizi E.S. Dopamine, as well as norepinephrine, is a link between noradrenergic nerve terminals and splenocytes. Brain Res. 1997, 761:236-243.
9. Ben-Eliyahu S. The promotion of tumor metastasis by surgery and stress: immunological basis and implications for psychoneuroimmunology. Brain Behav. Immun. 2003, 17(Suppl. 1):S27-S36.
10. Ben-Jonathan N., Hnasko R. Dopamine as a prolactin (PRL) inhibitor. Endocr. Rev. 2001, 22:724-763.
11. Birtwistle J., Baldwin D. Role of dopamine in schizophrenia and Parkinson's disease. Br. J. Nurs. 1998, 7:832-834.
12. Boneberg E.M., von Seydlitz E., Propster K., Watzl H., Rockstroh B., Illges H. D3 dopamine receptor mRNA is elevated in T cells of schizophrenic patients whereas D4 dopamine receptor mRNA is reduced in CD4+-T cells. J. Neuroimmunol. 2006, 173:180-187.
13. Boscarino J.A. Posttraumatic stress disorder and physical illness: results from clinical and epidemiologic studies. Ann. N. Y. Acad. Sci. 2004, 1032:141-153.
14. Cenci M.A. Dopamine dysregulation of movement control in l-DOPA-induced dyskinesia. Trends Neurosci. 2007, 30:236-243.
15. Cohen F., Kemeny M.E., Kearney K.A., Zegans L.S., Neuhaus J.M., Conant M.A. Persistent stress as a predictor of genital herpes recurrence. Arch. Intern. Med. 1993, 159:2430-2436.
16. Cosentino M., Rasini E., Colombo C., Marino F., Blandini F., Ferrari M., Samuele A., Lecchini S., Nappi G., Frigo G. Dopaminergic modulation of oxidative stress and apoptosis in human peripheral blood lymphocytes: evidence for a D1-like receptor-dependent protective effect. Free Radic. Biol. Med. 2004, 36(10):1233-1240.
17. Costantino C.M., Baecher-Allan C.M., Hafler D.A. Human regulatory T cells and autoimmunity. Eur. J. Immunol. 2008, 38:921-924.
18. Dayan P. Dopamine, reinforcement learning, and addiction. Pharmacopsychiatry 2009, 42(1):S56-S65.
19. De Bosscher K., Vanden Berghe W., Vermeulen L., Plaisance S., Boone E., Haegeman G. Glucocorticoids repress NF-kappa B driven genes by disturbing the interaction of p65 with the basal transcription machinery, irrespective of co-activator levels in the cell. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:3919-3924.
20. De Kloet C.S., Vermetten E., Bikker A., Meulman E., Geuze E., Kavelaars A., Westenberg H.G., Heijnen C.J. Leukocyte glucocorticoid receptor expression and immuneregulation in veterans with and without post-traumatic stress disorder. Mol. Psychiatry 2007, 12:443-453.
21. Djuardi Y., Sartono E., Wibowo H., Supali T., Yazdanbakhsh M. A longitudinal study of BCG vaccination in early childhood: the development of innate and adaptive immune responses. PLoS One 2010, 5(11):14066. 19.
22. Durant C., Christmas D., Nutt D. The pharmacology of anxiety. Curr. Top. Behav. Neurosci. 2010, 2:303-330.
23. Ekkens M.J., Liu Z., Liu Q., Whitmire J., Xiao S., Foster A., Pesce J., VanNoy J., Sharpe A.H., Urban J.F., Gause W.C. The role of OX40 ligand interactions in the development of the Th2 response to the gastrointestinal nematode parasite Heligmosomoides polygyrus. J. Immunol. 2003, 170(1):384-393.
24. Ferrari M., Cosentino M., Marino F., Bombelli R., Rasini E., Lecchini S., Frigo G. Dopaminergic D1-like receptor-dependent inhibition of tyrosine hydroxylase mRNA expression and catecholamine production in human lymphocytes. Biochem. Pharmacol. 2004, 67:865-873.
25. Ghosh M.C., Mondal A.C., Basu S., Banerjee S., Majumder J., Bhattacharya D., Dasgupta P.S. Dopamine inhibits cytokine release and expression of tyrosine kinases, Lck and Fyn in activated T cells. Int. Immunopharmacol. 2003, 3:1019-1026.
26. Gill J.M., Vythilingam M., Page G. Low cortisol, high DHEA, and high levels of TNF-a and IL-6 in women with PTSD. J. Trauma. Stress 2008, 21(6):530-539.
27. Gill J.M., Saligan L., Woods S., Page G. PTSD is associated with an excess of inflammatory immune activities. Perspect. Psychiatr. Care 2009, 45(4):262-277.
28. Godbout J.P., Glaser R. Stress-induced immune dysregulation: implications for wound healing, infectious disease and cancer. J. Neuroimmune Pharmacol. 2006, 1(421-427):2006.
29. Gotovac K., Sabioncello A., Rabatic S., Berki T., Dekaris D. Flow cytometric determination of glucocorticoid receptor (GCR) expression in lymphocyte subpopulations: lower quantity of GCR in individuals with post-traumatic stress disorder (PTSD). Clin. Exp. Immunol. 2003, 131:335-339.
30. Gutcher I., Becher B. APC-derived cytokines and T cell polarization in autoimmune inflammation. J. Clin. Invest. 2007, 117:1119-1125.
31. Hamilton M. The assessment of anxiety states by rating. Br. J. Med. Psychol. 1959, 32:50-55.
32. Holsboer F. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 2000, 23:477-501.
33. Ilani T., Ben-Shachar D., Strous R.D., Mazor M., Sheinkman A., Kotler M., Fuchs S. A peripheral marker for schizophrenia: Increased levels of D3 dopamine receptor mRNA in blood lymphocytes. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:625-628.
34. Jovanovic D.V., Di Battista J.A., Martel-Pelletier J., Jolicoeur F.C., He Y., Zhang M., Mineau F., Pelletier J.P. IL-17 stimulates the production and expression of pro-inflammatory cytokines, IL-beta and TNF-alpha, by human macrophages. J. Immunol. 1998, 160:3513-3521.
35. Kang D., Davidson R.J., Coe C.L., Wheeler R.E., Tomarken A.J., Erschler W.B. Frontal brain asymmetry and immune function. Behav. Neurosci. 1991, 105:860-869.
36. Kessler R.C., Chiu W.T., Demler O., Merikangas K.R., Walters E.E. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch. Gen. Psychiatry 2005, 62(6):617-627.
37. Khairova R.A., Machado-Vieira R., Du J., Manji H.K. A potential role for pro-inflammatory cytokines in regulating synaptic plasticity in major depressive disorder. Int. J. Neuropsychopharmacol. 2009, 12:561-578.
38. Khouzam H.R. Anxiety disorders: guidelines for effective primary care. Part 1: diagnosis. Consultant 2009, 49(3).
39. Kirillova G.P., Hrutkay R.J., Shurin M.R., Shurin G.V., Tourkova I.L., Vanyukov M.M. Dopamine receptors in human lymphocytes: radioligand binding and quantitative RT PCR assays. J. Neurosci. Methods 2008, 174:272-280.
40. Koh K.B., Lee Y. Reduced anxiety level by therapeutic interventions and cell-mediated immunity in panic disorder patients. Psychother. Psychosom. 2004, 73(5):286-292.
41. Kohn P.M., Kantor L., DeCicco T.L., Beck A.T. The Beck Anxiety Inventory-Trait (BAIT): a measure of dispositional anxiety not contaminated by dispositional depression. J. Pers. Assess. 2008, 90:499-506.
42. Lemieux A.M., Coe C.L. Abuse-related post-traumatic stress disorder: evidence of chronic neuroendocrine activation in women. Psychosom. Med. 1995, 57:105-115.
43. Lemieux A., Coe C.L., Carnes M. Symptom severity predicts degree of T cell activation in adult women following childhood maltreatment. Brain Behav. Immun. 2008, 22(6):994-1003.
44. Maes M., Bosmans E., Calabrese J., Smith R., Meltzer H.Y. Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers. J. Psychiatr. Res. 1995, 29:141-152.
45. Maestroni G.J., Mazzola P. Langerhans cells beta 2-adrenoceptors: role in migration, cytokine production, Th priming and contact hypersensitivity. J. Neuroimmunol. 2003, 144:91-99.
46. Marchant A., Goetghebuer T., Ota M.O., Wolfe I., Ceesay S.J., De Groote D., Corrah T., Bennett S., Wheeler J., Huygen K., Aaby P., McAdam K.P., Newport M.J. Newborns develop a Th1-type immune response to Mycobacterium bovis bacillus Calmette-Guérin vaccination. J. Immunol. 1999, 163:2249-2255.
47. Matsuzaki G., Umemura M. IL-17 as an effetor molecule of innate and acquired immunity against infections. Microbiol. Immunonol. 2007, 51:1139-1147.
48. McKenna F., McLaughlin P.J., Lewis B.J., Sibbring G.C., Cummerson J.A., Bowen-Jones D., Moots R.J. Dopamine receptor expression on human T- and B lymphocytes, monocytes, neutrophils, eosinophils and NK cells: a flow cytometric study. J. Neuroimmunol. 2002, 132:34-40.
49. Mills G.B., Schmandt R., Gibson S., Leung B., Hill M., May C., Shi Y.F., Branch D.R., Radvanyi L., Truitt K.E., et al. Transmembrane signaling by the interleukin-2 receptor: progress and conundrums. Semin. Immunol. 1993, 5:345-364.
50. Miossec P. IL-17 and Th17 cells in human inflammatory diseases. Microbiol. Infect. 2009, 11:625-630.
51. Muller N., Schwarz M.J. Immunology in anxiety and depression. Handbook of Depression and Anxiety 2002, 267-288. Marcel Dekker, New York. S. Kasper, J.A. den Boer, J.M.A. Sitsen (Eds.).
52. Muller N., Riedel M., Gruber R., Ackenheil M., Schwarz M.J. The immune system and schizophrenia. An integrative view. Ann. N. Y. Acad. Sci. 2000, 917:456-467.
53. Nakano K., Higashi T., Hashimoto K., Takagi R., Tanaka Y., Matsushita S. Antagonizing dopamine D1-like receptor inhibits Th17 cell differentiation: preventive and therapeutic effects on experimental autoimmune encephalomyelitis. Biochem. Biophys. Res. Commun. 2008, 373:286-291.
54. Nakano K., Matsushita S., Saito K., Yamaoka K., Tanaka Y. Dopamine as an immune-modulator between dendritic cells and T cells and the role of dopamine in the pathogenesis of rheumatoid arthritis. Nihon Rinsho Meneki Gakkai Kaishi 2009, 32:1-6.
55. Potvin S., Grignon S., Marchand S. Human evidence of a supra-spinal modulating role of dopamine on pain perception. Synapse 2009, 63:390-402.
56. Riedel M., Spellmann I., Schwarz M.J., Strassnig M., Sikorski C., Möller H.J., Müller N. Decreased T cellular immune response in schizophrenic patients. J. Psychiatr. Res. 2007, 41:3-7.
57. Saha B., Mondal A.C., Basu S., Dasgupta P.S. Circulating dopamine level, in lung carcinoma patients, inhibits proliferation and cytotoxicity of CD4+ and CD8+ T cells by D1 dopamine receptors: an in vitro analysis. Int. Immunopharmacol. 2001, 1:1363-1374.
58. Saha B., Mondal A.C., Majumder J., Basu S., Dasgupta P.S. Physiological concentrations of dopamine inhibit the proliferation and cytotoxicity of human CD4+CD8+ T cells in vitro: a receptor-mediated mechanism. Neuroimmunomodulation 2001, 9:23-33.
59. Sareen J., Cox B.J., Clara I., Asmundson G.J. The relationship between anxiety disorders and physical disorders in the U.S. National Comorbidity Survey. Depress. Anxiety 2005, 21:193-202.
60. Sarkar C., Basu B., Chakroborty D., Dasgupta P.S., Basu S. The immunoregulatory role of dopamine: an update. Brain Behav. Immun. 2010, 24:525-528.
61. Schneiderman N., Ironson G., Siegel S.D. Stress and health: psychological, behavioral, and biological determinants. Annu. Rev. Clin. Psychol. 2005, 1:607-628.
62. Sibley D.R., Monsma F.J., Shen Y. Molecular neurobiology of dopaminergic receptors. Int. Rev. Neurobiol. 1993, 35:391-415.
63. Sinha R. Chronic stress, drug use, and vulnerability to addiction. Ann. N. Y. Acad. Sci. 2008, 1141:105-130.
64. Spitzer R.L., Williams J.B., Gibbon M., First M.B. The Structured Clinical Interview for DSM-III-R (SCID). I: history, rationale, and description. Arch. Gen. Psychiatry 1992, 49(8):624-629.
65. Strange P.G. New insights into dopamine receptors in the central nervous system. Neurochem. Int. 1993, 22:223-236.
66. Strauman T.J., Woods T.E., Schneider K.L., Kwapil L., Coe C.L. Self-regulatory cognition and immune reactivity: idiographic success and failure feedback effects on the natural killer cell. Brain, Beh., Imm. 1993, 18:544-554.
67. Strous R.D., Shoenfeld Y. Schizophrenia. Autoimmunity and immune system dysregulation: a comprehensive model updated and revisited. J. Autoimmun. 2006, 27:71-80.
68. Sutherland A.G., Alexander D.A., Hutchison J.D. Disturbance of pro-inflammatory cytokines in post-traumatic psychopathology. Cytokine 2003, 24:219-225.
69. Takkouche B., Regueira C., Gestal-Otero J.J. A cohort study of stress and the common cold. Epidemiology 2001, 12:345-349.
70. Vazquez-Tello A., Semlali J., Chakir J.G., Martin D.Y., Leung D.H., Eidelman Q.Hamid Induction of glucocorticoid receptor-beta expression in epithelial cells of asthmatic airways by T-helper type 17 cytokines. Clin. Exp. Allergy 2010, 40:1312-1322.
71. Vieira M.M., Ferreira T.B., Pacheco P.A., Barros P.O., Almeida C.R., Araújo-Lima C.F., Silva-Filho R.G., Hygino J., Andrade R.M., Linhares U.C., Andrade A.F., Bento C.A. Enhanced Th17 phenotype in individuals with generalized anxiety disorder. J. Neuroimmunol. 2010, 229(1-2):212-218.
72. Vignali D.A., Collison L.W., Workman C.J. How regulatory T cells work. Nat. Rev. Immunol. 2008, 8:523-532.
73. von Känel R., Hepp U., Kraemer B., Traber R., Keel M., Mica L., Schnyder U. Evidence for low-grade systemic proinflammatory activity in individuals with posttraumatic stress disorder. J. Psych. Res. 2007, 41:744-752.
74. Wessa M., Rohleder N. Endocrine and inflammatory alterations in posttraumatic stress disorder. Expert Rev. Endocrinol. Metab. 2007, 2:91-122.
75. Wilson S., van der Kolk B., Burbridge J., Fisler R., Kradin R. Phenotype of blood lymphocytes in PTSD suggests chronic immune activation. Psychosomatics 1999, 40:222-225.
76. Wise R.A. Dopamine and reward: the anhedonia hypothesis 30years on. Neurotox. Res. 2008, 14:169-183.
77. Zhou F.L., Zhang W.G., Wei Y.C., Xu K.L., Hui L.Y., Wang X.S., Li M.Z. Impact of comorbid anxiety and depression on quality of life and cellular immunity changes in patients with digestive tract cancers. World J. Gastroenterol. 2005, 11(15):2313-2318.